NasdaqGS · Biotechnology

LENZ Therapeutics, Inc. (LENZ)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+412.8%

$24.00 average target

$4.68+0.02 (+0.4%)Latest market snapshot · Yahoo Finance

Market cap$147.0M

Cash$220.0M

Quarterly burn$33.6M

Pipeline assets2

Short float59.5%

Clinical portfolio

LENZ Therapeutics, Inc. Drug Pipeline

Showing 0 of 2

Pipeline data is not currently available

The page remains usable with the verified company and catalyst data already on file.

Continue with BioPharma ProUnlock 2 additional programs and complete development details.

Unlock Pro

Upcoming milestones

LENZ Catalyst Timeline

0 currently tracked

Dated catalysts is not currently available

The page remains usable with the verified company and catalyst data already on file.

Company profile

About LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.